Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma

Oncology Reports

Volumn 19, Issue 2, 2008, Pages 425-433

  Ko, Seong Hee ^a   Choi, Geun Jun ^a   Lee, Ji Hye ^a   Han, Yoon A ^a   Lim, Soo Jeong ^b   Kim, So Hee ^a  

^a Gangneung Wonju National University   (South Korea)

^b Sejong University   (South Korea)

Author keywords

Apoptosis; Celecoxib; Cyclooxygenase 2 inhibitor; KB cell; Multidrug resistance; Oral squamous cell carcinoma

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CASPASE 3; CASPASE 7; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA FRAGMENT; MELOXICAM; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIMESULIDE; PROSTAGLANDIN E2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; INHIBITION KINETICS; MOUTH CARCINOMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

EID: 38749104628     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.2.425     Document Type: Article

References (32)

1. Nystrom ML, McCulloch D, Weinreb PH, Violette SM, Speight PM, Marshall JF, Hart IR and Thomas GJ: Cyclooxygenase-2 inhibition suppresses alphavbeta6 integrin-dependent oral squamous carcinoma invasion. Cancer Res 66: 1833-10842, 2006.
2. Day GL and Blot WJ: Second primary tumors in patients with oral cancer. Cancer 70: 14-19, 1992.
3. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB and Subbaramaiah K: Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol 2: 544-551, 2001.
4. Shiff SJ and Rigas B: Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology 113: 1992-1998, 1997.
5. Williams CS, Mann M and DuBois RN: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18: 7908-7916, 1999.
6. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R and Ahnen DJ: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116, 1995.
7. Shiff SJ, Koutsos MI, Qiao L and Rigas B: Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cell effects on cell cycle and apoptosis. Exp Cell Res 222: 179-188, 1996.
8. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD and DuBois RN: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99: 2254-2259, 1997.
9. Souza RF, Sheqmake K, Beer DG, Cryer B and Spechler SJ: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60: 5767-5772, 2000.
10. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI and Rigas B: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 25: 237-245, 1996.
11. Elder DJ, Halton DE, Hague A and Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 3: 1679-1683, 1997.
12. Smith ML, Hawcroft C and Hull MA: The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 36: 664-674, 2000.
13. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woemer BM, Masferrer JL and Dannenberg AJ: Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59: 991-994, 1999.
14. Nicolini G, Miloso M, Moroni MC, Beguinot L and Scotto L: Post-transcriptional control regulates transforming growth factor alpha in the human carcinoma KB cell line. J Biol Chem 271: 30290-30296, 1996.
15. Jackson LM and Hawkey CJ: COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 59: 1207-1216, 2000.
16. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM and Burton J: Celecoxib exhibits the greatest amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62: 2029-2033, 2002.
17. Tewari M, Quan LT, L'Rourke K, Desnovers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM: Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809, 1995.
18. Smartt HJ, Elder DJ, Hicks DJ, Williams NA and Paraskeva C: Increased NF-kappaB DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cells. Br J Cancer 89: 1358-1365, 2003.
19. Han S and Roman J: COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer 51: 283-296, 2006.
20. Simeone AM, Li YJ, Broemeling LD, Johnson MM, Tuna M and Tari AM: Cyclooxygenase-2 is essential for HER2/neu to suppress N-(4-hydroxyphenyl) retinamide apoptotic effects in breast cancer cells. Cancer Res 64: 1224-1228, 2004.
21. Nishimura N, Urade M, Hashitani S, Noguchi K, Manno Y, Takaoka K and Sakurai K: Increased expression of cyclooxygenase (COX)-2 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 33: 614-621, 2004.
22. Shiotani H, Denda A, Yamamoto K, Kitayama W, Endoh T, Sasaki Y, Tsutsumi M, Sugimura M and Konishi Y: Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res 61: 1451-1456, 2001.
23. Naruse T, Nishida Y, Hosono K and Ishiguro N: Meloxicam inhibits osteosarcoma growth, invasiveness and memstasis by COX-2-dependent and independent routes. Carcinogenesis 27: 584-592, 2006.
24. Wang Z, Fuentes CF and Shapshay SM: Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope 112: 839-843, 2002.
25. Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D and Nagumo M: Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis 21: 737-745, 2004.
26. Yamazaki R, Kusunoki N, Matsuzaki T, Hashmoto S and Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferators-activated receptor γ in rheumatoid synovial cells. J Pharmacol Exp Ther 302: 18-25, 2002.
27. Yoshida K, Hirose Y, Tanaka T, Yamada Y, Kuno T, Kohno H, Katayama M, Qiao Z, Sakata K, Sugie S, Shibata T and Mori H: Inhibitory effects of troglitazone, a peroxisome proliferators-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide. Cancer Sci 94: 365-371, 2003.
28. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G and Murcia JM: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273: 33533-33539, 1998.
29. Grösch S, Tegeder I, Niederberger E, Bräutigam L and Geisslinger G: COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15: 2742-2744, 2001.
30. Lee EJ, Kim SH, Kwark YE and Kim J: Heterogeneous nuclear ribonuclear protein C is increased in the celecoxib-induced growth inhibition of human oral squamous cell carcinoma. Exp Mol Med 38: 203-209, 2006.
31. Kardosh A, Soriano N, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen TC and Schonthal AH: Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 106: 4330-4338, 2005.
32. Zheng WB, Wang CH, Qiang O and Tang CW: Inhibitory effects of celecoxib combined with octreotide on growth of multidrug resistant human gastric cancer cell line SGC7901/ADR. Ai Zheng 23: 1628-1632, 2004.